Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villeurbanne – page 139

2 127 clinical trials in Villeurbanne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villeurbanne at a glance
2 127
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 127 trials in Villeurbanne

Open in trial search

Osteochondrodysplasia

Not recruiting

Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Cervix carcinoma

Not recruiting

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Villeurbanne

What the registry says about research in the country

01 Neurodegenerative Diseases

Extensive research focusing on Alzheimer's disease treatments, including multiple studies evaluating novel therapeutic approaches for early-stage patients. Additional investigations examine Parkinson's disease and serotonergic receptor expression.

  • Early Alzheimer's Disease Interventions
  • Parkinson's Disease Mechanisms
  • Cognitive Function Assessment

Studies utilize innovative compounds and treatment strategies to address disease progression and symptoms.

02 Cardiovascular Health

Innovative research targeting heart failure prevention through combination therapy approaches. Studies evaluate new treatment strategies for reducing cardiovascular risks and improving patient outcomes.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Combined Therapeutic Approaches

Focus on preventive strategies and risk reduction in high-risk populations.

03 Oncology Research

Comprehensive studies in various cancer types, including colorectal cancer, breast cancer, and gastric cancer. Research emphasizes personalized treatment approaches and innovative therapeutic strategies.

  • Colorectal Cancer Treatment
  • Breast Cancer Hormone Therapy
  • Gastrointestinal Oncology

Trials incorporate advanced diagnostic methods and targeted therapies.

04 Respiratory Medicine

Studies examining treatments for severe asthma and COPD, evaluating new therapeutic combinations and investigating treatment responses in respiratory conditions.

  • Asthma Management
  • COPD Interventions
  • Respiratory Treatment Optimization

Focus on improving pulmonary outcomes and patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.